Twitter

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Condition:   Malignant Melanoma
Intervention:   Drug: Zelboraf (vemurafenib)
Sponsors:   Genentech;   Genentech
Recruiting – verified April 2012

Read more here: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E




Comments are closed.